In addition p53 knockout HCT116 colon cancer cells, which harbor oncogenic KRAS, are also more sensitive to CmpdA treatment than p53 WT HCT116 cells (Supplementary Fig. S2). This evidence concerns the gene TP53 and malignant colon neoplasm.